UNITY Biotechnology

The future of DME treatment may lie in new mechanisms beyond VEGF inhibition, and the potential impact for patients is significant.? ? Recent data from our Phase 2b ASPIRE Study found that UBX1325 generally outperformed aflibercept in patients who had moderate disease severity (baseline CST < 400 microns, representing ~60% of study patients), potentially addressing a much-needed treatment breakthrough for DME patients who have exhausted existing therapies.? ? See the ASPIRE Phase 2b data:?https://bit.ly/3RjoS5R Robert Bhisitkul

Today we announced topline results from the Phase 2b ASPIRE clinical trial of intravitreal UBX1325 in patients with diabetic macular edema (#DME) who had poor vision despite prior anti-VEGF treatment. ? Read the full announcement: https://lnkd.in/g2y-52_t

Today, we welcomed Yehia Hashad MD to our board of directors and as a member of the board’s science committee. Dr. Hashad is an experienced ophthalmologist and pharmaceutical executive who will help guide the continued execution of our strategic vision as we anticipate receiving the 24-week data from our Phase 2b ASPIRE study in #DME this quarter.? ? Learn more: https://lnkd.in/g6pCEjXi

Today we announced our Q4 and full year 2024 financial results and business updates, including progress on our senolytic pipeline and the upcoming 24-week topline data from our Phase 2b ASPIRE study in diabetic macular edema (#DME). ? See the full release: https://lnkd.in/gWTBeUDz

The growing DME population has significant unmet needs, with many patients experiencing suboptimal treatment response, vision decline, and a high treatment burden. At UNITY, we are committed to advancing innovative solutions for DME patients. UBX1325 offers a novel approach aimed at improving visual outcomes through a proven intravitreal route, potentially helping patients maintain their vision and independence. Learn more from our chief strategy officer Alicia Tozier below. Stay tuned as we share topline results from our Phase 2b ASPIRE study evaluating UBX1325 in #DME patients.

While anti-VEGF injections are the current standard of care, the need for frequent dosing and limited treatment benefit in many patients creates a significant burden for patients and family members who routinely schedule doctor’s appointments and check-ups.? ? That’s where senolytic therapies could potentially come in. Instead of just managing symptoms, #UBX1325 aims to eliminate senescent cells—the source of inflammation and VEGF production in the eye—thereby potentially reducing the need for frequent treatment and addressing true disease modification.?? ? Stay tuned as we share topline results from our Phase 2b ASPIRE study evaluating UBX1325 in #DME patients who are not achieving optimal benefit from anti-VEGF drugs.?

To our dedicated staff—you are the heart of our company.? ? At UNITY, we foster an inclusive culture that celebrates individuality and embraces our rich diversity.?As a cornerstone of our company, we value integrity, compassion, and mutual respect across the whole team, embracing openness and unique perspectives. We’re grateful to our wonderful team for continuously embodying the heart of UNITY!?#EmployeeAppreciation

UNITY is at the forefront of developing the first ever senolytic candidate that aims to restore diseased tissues to a healthier state. See how #UBX1325 targets senescent cells in the diabetic retina, clearing inflammation and potentially restoring vision in #DME patients.?

Where can patients with #DME turn to after standard-of-care anti-VEGF treatments stop providing benefit? #UBX1325’s novel mechanism of action has the potential to deliver additional visual improvements with fewer injections, even after anti-VEGF therapy. At our last Ophthalmology Day, Dante Joseph Pieramici, M.D. of California Retina Consultants explained the excitement behind the new industry MOA. UNITY’s senolytic approach is a glimpse into how rethinking disease pathways can redefine DME treatment possibilities. Learn more about our vision and listen to our full Ophthalmology Day for Investors and Analysts presentation: https://bit.ly/3XpnuCP

Ever wonder what our executives’ lives are like outside of advancing our #DME senolytic candidate? Our chief medical officer?Federico Grossi, M.D., Ph.D.?talked about his garage-turned-workshop and the most recent project he’s been working on with his son?in this week’s edition of?STAT’s “Up and down the ladder.” ? Read the article here: https://lnkd.in/gcDspmkJ